This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

MELA Sciences Names Rpr Marketing Communications As Its New Agency Of Record

NEW YORK,
Jan. 3, 2013 /PRNewswire/ --
MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that developed
MelaFind®, a breakthrough device intended to help dermatologists detect melanoma when it is still curable, announced today that it has named Rpr Marketing Communications as its U.S. public relations agency of record.

"This partnership is a natural fit given both companies' unique expertise in skin cancer detection," said
Joseph V. Gulfo, MD, President & CEO of MELA Sciences. "By driving awareness around melanoma detection, including the importance of annual mole checks and advanced diagnostic tools like MelaFind, we hope to help eradicate this deadly epidemic."

Rpr Marketing Communications will provide a full range of marketing communications based services, including consumer and professional media relations, corporate communications, professional meeting strategy and special initiative management. The
New York City based agency has extensive experience within the aesthetic medicine, personal care and skincare industries, with proven success in the skin cancer awareness community.

"We planned to engage a marketing communications firm in the second half of our launch year to help us achieve our goals," said Dr. Gulfo. "We chose Rpr after our search process because of their proven track record of widespread brand acceptance and adoption of products within our space.

Nearly one in five people are likely to get skin cancer this year. There are an estimated 130,000 new cases of melanoma diagnosed in the U.S. every year and according to the National Institutes of Health, 16 percent are diagnosed only after the disease has spread to other parts of the body. Nearly all patients diagnosed with early-stage melanoma can be treated and cured, but 85 percent of patients with late-stage melanoma die from it within five years.

Product Features:

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.